R-ketorolac as a GTPase inhibitor: Phase 0 intraperitoneal pharmacokinetic and biologic activity in ovarian cancer patients

MLA

Yuna Guo, et al. “R-Ketorolac as a GTPase Inhibitor: Phase 0 Intraperitoneal Pharmacokinetic and Biologic Activity in Ovarian Cancer Patients.” Gynecologic Oncology, vol. 133, June 2014, p. 56. EBSCOhost, https://doi.org/10.1016/j.ygyno.2014.03.155.

APA

Yuna Guo, SR Kenney, M. Gaede, Sarah Adams, Carolyn Y. Muller, Laurie G. Hudson, Angela Wandinger-Ness, & Teresa Rutledge. (2014). R-ketorolac as a GTPase inhibitor: Phase 0 intraperitoneal pharmacokinetic and biologic activity in ovarian cancer patients. Gynecologic Oncology, 133, 56. https://doi.org/10.1016/j.ygyno.2014.03.155

Chicago

Yuna Guo, SR Kenney, M. Gaede, Sarah Adams, Carolyn Y. Muller, Laurie G. Hudson, Angela Wandinger-Ness, and Teresa Rutledge. 2014. “R-Ketorolac as a GTPase Inhibitor: Phase 0 Intraperitoneal Pharmacokinetic and Biologic Activity in Ovarian Cancer Patients.” Gynecologic Oncology 133 (June): 56. doi:10.1016/j.ygyno.2014.03.155.